PLEKHA7 activators refer to a class of chemical compounds that interact with cellular pathways to upregulate the expression or function of PLEKHA7, a protein associated with tight junctions in epithelial cells. These activators work at various levels of cellular regulation, including gene transcription, mRNA stabilization, protein translation, and post-translational modifications. The mechanisms by which these activators function are diverse, reflecting the complexity of cellular signaling and gene expression regulation. For instance, some activators may bind directly or indirectly to promoter regions of the PLEKHA7 gene, enhancing its transcription by altering the chromatin structure to a more accessible state for transcription factors. Others may influence the stability of PLEKHA7 mRNA, protecting it from degradation and thereby increasing the translation rate and protein abundance.
Beyond transcriptional regulation, PLEKHA7 activators can also affect the protein at a post-translational level. Some chemicals in this class may inhibit the pathways that target PLEKHA7 for degradation, such as the ubiquitin-proteasome system, thus extending the half-life of the protein within the cell. Additionally, post-translational modifications like phosphorylation, ubiquitination, or sumoylation can be modulated by PLEKHA7 activators, which in turn can alter the protein's activity, localization, or interaction with other proteins. These activators are often investigated in the context of cellular biology and biochemistry to understand the intricate web of interactions that govern cell adhesion and communication. The aim is to delineate the detailed molecular pathways through which PLEKHA7 activators exert their effects, thereby contributing to a deeper comprehension of the cellular functions that PLEKHA7 supports, particularly in maintaining the structure and function of tight junctions in epithelial cells.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, an HDAC inhibitor, may indirectly upregulate PLEKHA7 by increasing the acetylation of histones, leading to a more open chromatin structure and potentially higher gene transcription levels. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
As a DNA methyltransferase inhibitor, 5-Azacytidine could potentially lead to the demethylation of the PLEKHA7 gene promoter, enhancing its transcription. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid, a derivative of vitamin A, modulates gene expression through its receptors and may upregulate PLEKHA7 by binding to retinoic acid response elements in its promoter region. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased cAMP levels, which can modulate various signaling pathways and potentially increase PLEKHA7 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is involved in protein synthesis; paradoxically, this inhibition could lead to compensatory mechanisms that upregulate proteins like PLEKHA7. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that could prevent the degradation of transcription factors that enhance PLEKHA7 expression or stabilize PLEKHA7 protein directly. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium can affect the Wnt signaling pathway, which may influence PLEKHA7 expression due to the pathway's role in cell polarity and junction formation. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus, which might lead to a stress response that upregulates certain proteins, potentially including PLEKHA7. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
This agent induces ER stress and the unfolded protein response, which could lead to changes in gene expression, including possibly upregulating PLEKHA7. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin elevates intracellular calcium levels, which may activate calcium-dependent signaling pathways affecting PLEKHA7 expression. | ||||||